Success sets Brisbane medtech company DoseMe up for U.S. market

"It was 2012 and Dr Robert McLeay was chatting to his wife’s colleague at a backyard Brisbane barbecue. While enjoying his burger, McLeay listened intently to a story about a scientific innovation not yet easily available to clinicians, but which should have been. The discussion involved Bayesian dosing, which allows clinicians to dose a patient based on that patient’s individual ability to absorb, process, and clear a drug from their system.Working on his PHD in medical research at the time, McLeay’s interest was piqued. After the pavlova was served, he couldn’t get home fast enough. He went on to develop DoseMe’s first prototype that weekend." Read more

Andrea Martins Tech Street Journal 14 Sep 2016